trending Market Intelligence /marketintelligence/en/news-insights/trending/RmPygeUTttLx82wt7p2wvg2 content esgSubNav
In This List

GW Pharmaceuticals prices offering of ADSs

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


GW Pharmaceuticals prices offering of ADSs

GW Pharmaceuticals plc priced an underwritten public offering on the Nasdaq Global Market of 2,400,000 American depositary shares at $115 apiece.

The ADSs represent 28,800,000 ordinary shares of GW.

The U.K.-based company expects gross proceeds of about $276 million from the offering.

GW Pharmaceuticals granted underwriters a 30-day option to buy up to an additional 360,000 ADSs at the offering price.

The offering is expected to close Dec. 11.

Goldman Sachs & Co. LLC, Morgan Stanley, Bank of America Merrill Lynch and Cowen are acting as joint book-running managers for the offering.